Press Release: Entasis : Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints --- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints